Epidemiology and treatment outcome of ANCA-associated vasculitis in South Korea: a nationwide, population-based cohort study.
暂无分享,去创建一个
[1] F. Ferro,et al. Systemic vasculitis: one year in review 2023. , 2023, Clinical and experimental rheumatology.
[2] M. Englund,et al. Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study , 2023, RMD Open.
[3] R. Luqmani,et al. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. , 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] Yong-Beom Park,et al. Secular Trends of Incidence, Prevalence, and Healthcare Economic Burden in ANCA-Associated Vasculitis: An Analysis of the 2002–2018 South Korea National Health Insurance Database , 2022, Frontiers in Medicine.
[5] Juhee Cho,et al. Association between the presence of delirium during intensive care unit admission and cognitive impairment or psychiatric problems: the Korean ICU National Data Study , 2022, Journal of Intensive Care.
[6] Min Chen,et al. Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients , 2021, BMC Pulmonary Medicine.
[7] Y. Kim,et al. Impact of kidney transplantation on the risk of retinal vein occlusion in end-stage renal disease , 2021, Scientific Reports.
[8] C. Moon,et al. The cancer risk according to three subtypes of ANCA-associated vasculitis: A propensity score-matched analysis of a nationwide study. , 2021, Seminars in arthritis and rheumatism.
[9] J. Stone,et al. ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry , 2021, The Journal of Rheumatology.
[10] Su Hwan Lee,et al. Impact of Intensivist and Nursing Staff on Critically Ill Patient Mortality: A Retrospective Analysis of the Korean NHIS Cohort Data, 2011–2015 , 2020, Yonsei medical journal.
[11] W. Koldingsnes,et al. Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. , 2019, Rheumatology.
[12] J. Stone,et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. , 2019, Rheumatology.
[13] J. Yoon,et al. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011–2015 , 2019, Orphanet Journal of Rare Diseases.
[14] D. Misra,et al. Is granulomatosis with polyangiitis in Asia different from the West? , 2018, International journal of rheumatic diseases.
[15] J. Esdaile,et al. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies , 2017, Annals of the rheumatic diseases.
[16] P. Merkel,et al. Trends in Long‐Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Renal Disease , 2016, Arthritis & rheumatology.
[17] A. Farr,et al. Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States , 2015, The Journal of Rheumatology.
[18] N. Basu,et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] S. Ito,et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study , 2014, Arthritis Research & Therapy.
[20] F. Vandergheynst,et al. ANCA-ASSOCIATED VASCULITIS , 2013, Acta clinica Belgica.
[21] D. Reid,et al. The characterisation and determinants of quality of life in ANCA associated vasculitis , 2013, Annals of the rheumatic diseases.
[22] D. Scott,et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. , 2012, Rheumatology.
[23] D. Scott,et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. , 2011, Rheumatology.
[24] P. Merkel,et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.
[25] L. Jacobsson,et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.
[26] D. Scott,et al. Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype? , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] D. Scott,et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe , 2001, Annals of the rheumatic diseases.
[28] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.